BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
- Published in:
- Laboratory Medicine, 2019, v. 50, n. 4, p. 401, doi. 10.1093/labmed/lmz008
- By:
- Publication type:
- Article